Axonics, Inc. (NASDAQ:AXNX) Given Consensus Recommendation of “Hold” by Brokerages

Axonics, Inc. (NASDAQ:AXNXGet Free Report) has been given a consensus recommendation of “Hold” by the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $70.30.

A number of brokerages recently issued reports on AXNX. Royal Bank of Canada reiterated a “sector perform” rating and issued a $71.00 price objective on shares of Axonics in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research report on Monday, May 6th.

Check Out Our Latest Report on AXNX

Axonics Price Performance

Axonics stock opened at $67.13 on Friday. The firm has a market capitalization of $3.42 billion, a P/E ratio of -209.78 and a beta of 0.60. Axonics has a one year low of $47.59 and a one year high of $69.68. The business has a fifty day moving average price of $67.60 and a 200-day moving average price of $65.20.

Axonics (NASDAQ:AXNXGet Free Report) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.32). Axonics had a negative net margin of 4.12% and a negative return on equity of 2.58%. The company had revenue of $91.41 million for the quarter, compared to the consensus estimate of $89.79 million. During the same quarter in the prior year, the company earned ($0.19) earnings per share. The company’s quarterly revenue was up 29.4% on a year-over-year basis. Sell-side analysts expect that Axonics will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of Axonics

Several institutional investors have recently added to or reduced their stakes in the business. NBC Securities Inc. boosted its stake in shares of Axonics by 106.4% during the fourth quarter. NBC Securities Inc. now owns 673 shares of the company’s stock valued at $41,000 after purchasing an additional 347 shares during the period. Headlands Technologies LLC purchased a new stake in Axonics during the 4th quarter valued at $53,000. RiverPark Advisors LLC purchased a new stake in Axonics during the 3rd quarter valued at $58,000. C M Bidwell & Associates Ltd. grew its holdings in Axonics by 108.2% in the 3rd quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock worth $71,000 after acquiring an additional 660 shares during the last quarter. Finally, Whittier Trust Co. increased its position in shares of Axonics by 59.1% in the first quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock valued at $79,000 after acquiring an additional 424 shares during the period. 99.48% of the stock is currently owned by hedge funds and other institutional investors.

About Axonics

(Get Free Report

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.

Further Reading

Analyst Recommendations for Axonics (NASDAQ:AXNX)

Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with's FREE daily email newsletter.